<div id="readability-page-1"><p>Krilogy Financial LLC grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 92.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 20,872 shares of the company's stock after purchasing an additional 10,050 shares during the period. Krilogy Financial LLC's holdings in CRISPR Therapeutics were worth $1,127,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>CRISPR Therapeutics</strong> alerts:</span></p></div><ul><li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices </li></ul><p>A number of other institutional investors also recently modified their holdings of the business. Nordea Investment Management AB grew its holdings in CRISPR Therapeutics by 40.8% during the 1st quarter. Nordea Investment Management AB now owns 148,700 shares of the company's stock valued at $10,305,000 after buying an additional 43,100 shares in the last quarter. Congress Asset Management Co. MA grew its position in shares of CRISPR Therapeutics by 60.3% during the 1st quarter. Congress Asset Management Co. MA now owns 64,605 shares of the company's stock valued at $4,403,000 after purchasing an additional 24,303 shares in the last quarter. PBCay One RSC Ltd bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth $10,329,000. Cetera Investment Advisers increased its stake in CRISPR Therapeutics by 451.3% in the 1st quarter. Cetera Investment Advisers now owns 34,100 shares of the company's stock worth $2,324,000 after acquiring an additional 27,915 shares during the last quarter. Finally, CWM LLC raised its stake in CRISPR Therapeutics by 11,871.1% in the second quarter. CWM LLC now owns 22,386 shares of the company's stock valued at $1,209,000 after purchasing an additional 22,199 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several analysts have weighed in on the company. Robert W. Baird boosted their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, May 9th. Rodman &amp; Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a &#34;buy&#34; rating and a $90.00 price objective for the company. Needham &amp; Company LLC lowered their target price on CRISPR Therapeutics from $88.00 to $84.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, August 6th. Barclays reduced their target price on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Tuesday, August 6th. Finally, Guggenheim reiterated a &#34;neutral&#34; rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $75.63.</p><br/><ul><li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval </li></ul><p><b>Read Our Latest Analysis on CRSP</b></p><h2>CRISPR Therapeutics Price Performance</h2><p>Shares of CRSP traded up $0.92 during trading hours on Wednesday, hitting $49.99. The stock had a trading volume of 1,108,313 shares, compared to its average volume of 1,573,917. The firm has a market capitalization of $4.25 billion, a PE ratio of -18.17 and a beta of 1.70. The stock has a fifty day moving average price of $55.02 and a 200 day moving average price of $61.96. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10. </p><ul><li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li></ul><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. During the same period in the previous year, the company earned ($0.98) earnings per share. The business's revenue for the quarter was down 99.3% compared to the same quarter last year. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.52 EPS for the current fiscal year. </p><h2>Insider Activity</h2><p>In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 4.10% of the company's stock. </p><h2>CRISPR Therapeutics Profile</h2> (Free Report)<p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p><h2>See Also</h2><ul><li>Five stocks we like better than CRISPR Therapeutics</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>Target Hits the Mark: Q2 Earnings Exceed Expectations</li><li>Breakout Stocks: What They Are and How to Identify Them</li><li>Is Tesla’s Rebound Just Starting? Why You Should Consider Buying</li><li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li><li>Stanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Trump is sounding the alarm <span><span>(From Preserve Gold)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3"/></p><h2>Should you invest $1,000 in CRISPR Therapeutics right now?</h2><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p><p>While CRISPR Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

CRSP

<p>Krilogy Financial LLC increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 92.9% in Q2, acquiring 10,050 shares, bringing its total holdings to 20,872 shares worth $127,000. Other institutional investors have also raised their stakes. Analysts have provided varying price targets and ratings, with a consensus rating of "Hold" and an average target price of $66.63. Despite trading activity, CRISPR's stock posted a quarterly loss per share of $0.49, missing estimates, as revenue decreased significantly compared to last year.</p>

Krilogy Financial LLC Acquires 10,050 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)